Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Vitamin D and Omega-3 Polyunsaturated Fatty Acids in Type 1 Diabetes Modulation

Author(s): Thais Sibioni Berti Bastos, Tárcio Teodoro Braga and Mariana Rodrigues Davanso*

Volume 22, Issue 8, 2022

Published on: 21 April, 2022

Page: [815 - 833] Pages: 19

DOI: 10.2174/1871530322666220103114450

Price: $65

Abstract

Background: Type 1 diabetes (T1D) is a chronic autoimmune disease affecting people globally. Usually developed during childhood, T1D is characterized by the destruction of pancreatic β-cells due to immune cell attack and the establishment of an inflammatory process.

Objective: The study aimed to investigate the effects of vitamin D through its nuclear receptor and the ω-3 polyunsaturated fatty acids (PUFAs) through their lipid derivatives in T1D modulation. Both components exert anti-inflammatory activity and act directly on cells of the immune system, attenuating the destruction of insulin-producing cells. Furthermore, they lead to a better glycemic level, reducing the need for insulin and a normal immune state, such as C-peptide maintenance.

Methods: Presently, our review highlights the significant studies that evaluated the supplementation of vitamin D and ω-3 PUFAs in humans and animal models in the modulation of T1D.

Conclusion: The data collected suggests that supplementation can provide potential benefits, mainly when done early in the diagnosis, since it reduces the need for insulin and the risk of complications generated by the disease.

Keywords: Type 1 diabetes (T1D), vitamin D, ω-3 polyunsaturated fatty acids (PUFAs), animal models, anti-inflammatory, supplementation.

« Previous Next »
Graphical Abstract

[1]
Wolden-Kirk, H.; Overbergh, L.; Christesen, H.T.; Brusgaard, K.; Mathieu, C. Vitamin D and diabetes: its importance for beta cell and immune function. Mol. Cell. Endocrinol., 2011, 347(1-2), 106-120.
[http://dx.doi.org/10.1016/j.mce.2011.08.016] [PMID: 21889571]
[2]
WHO Classification of diabetes mellitus 2019; World Health Organization: Geneva, 2019.
[3]
Rowley, W.R.; Bezold, C.; Arikan, Y.; Byrne, E.; Krohe, S. Diabetes 2030: insights from yesterday, today, and future trends. Popul. Health Manag., 2017, 20(1), 6-12.
[http://dx.doi.org/10.1089/pop.2015.0181] [PMID: 27124621]
[4]
Ogurtsova, K.; da Rocha Fernandes, J.D.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.E.; Makaroff, L.E. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract., 2017, 128, 40-50.
[http://dx.doi.org/10.1016/j.diabres.2017.03.024] [PMID: 28437734]
[5]
Muscogiuri, G.; Mitri, J.; Mathieu, C.; Badenhoop, K.; Tamer, G.; Orio, F.; Mezza, T.; Vieth, R.; Colao, A.; Pittas, A. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. Eur. J. Endocrinol., 2014, 171(3), R101-R110.
[http://dx.doi.org/10.1530/EJE-14-0158] [PMID: 24872497]
[6]
Ramos-Lopez, E.; Jansen, T.; Ivaskevicius, V.; Kahles, H.; Klepzig, C.; Oldenburg, J.; Badenhoop, K. Protection from type 1 diabetes by vitamin D receptor haplotypes. Ann. N. Y. Acad. Sci., 2006, 1079, 327-334.
[http://dx.doi.org/10.1196/annals.1375.050] [PMID: 17130574]
[7]
Mishra, A.; Dayal, D.; Sachdeva, N.; Attri, S.V. Effect of 6-months’ vitamin D supplementation on residual beta cell function in children with type 1 diabetes: a case control interventional study. J. Pediatr. Endocrinol. Metab., 2016, 29(4), 395-400.
[http://dx.doi.org/10.1515/jpem-2015-0088] [PMID: 26244673]
[8]
Caprio, M.; Infante, M.; Calanchini, M.; Mammi, C.; Fabbri, A. Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects. Eat Weight Disord. – Stud. Anorexia. Bulim. Obes., 2016, 22, 27-41.
[9]
Prietl, B.; Treiber, G.; Pieber, T.R.; Amrein, K. Vitamin D and immune function. Nutrients, 2013, 5(7), 2502-2521.
[http://dx.doi.org/10.3390/nu5072502] [PMID: 23857223]
[10]
Ferreira, G.B.; Vanherwegen, A.S.; Eelen, G.; Gutiérrez, A.C.F.; Van Lommel, L.; Marchal, K.; Verlinden, L.; Verstuyf, A.; Nogueira, T.; Georgiadou, M.; Schuit, F.; Eizirik, D.L.; Gysemans, C.; Carmeliet, P.; Overbergh, L.; Mathieu, C. Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways. Cell Rep., 2015, 10(5), 711-725.
[http://dx.doi.org/10.1016/j.celrep.2015.01.013] [PMID: 25660022]
[11]
Yates, C.M.; Calder, P.C.; Ed Rainger, G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol. Ther., 2014, 141, 272-282.
[http://dx.doi.org/10.1016/j.pharmthera.2013.10.010]
[12]
Infante, M.; Ricordi, C.; Padilla, N.; Alvarez, A.; Linetsky, E.; Lanzoni, G.; Mattina, A.; Bertuzzi, F.; Fabbri, A.; Baidal, D.; Alejandro, R. The role of vitamin D and omega-3 PUFAs in islet transplantation. Nutrients, 2019, 11(12), 2937.
[http://dx.doi.org/10.3390/nu11122937] [PMID: 31816979]
[13]
Park, M.; Lim, J.W.; Kim, H. Docoxahexaenoic acid induces apoptosis of pancreatic cancer cells by suppressing activation of STAT3 and Nf-κB. Nutrients, 2018, 10, 1-14.
[http://dx.doi.org/10.3390/nu10111621]
[14]
Bi, X.; Li, F.; Liu, S.; Jin, Y.; Zhang, X.; Yang, T.; Dai, Y.; Li, X.; Zhao, A.Z. ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J. Clin. Invest., 2017, 127(5), 1757-1771.
[http://dx.doi.org/10.1172/JCI87388] [PMID: 28375156]
[15]
Baidal, D.A.; Ricordi, C.; Garcia-Contreras, M.; Sonnino, A.; Fabbri, A. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(15), 3313-3318.
[PMID: 27467009]
[16]
Cadario, F.; Savastio, S.; Rizzo, A.M.; Carrera, D.; Bona, G.; Ricordi, C. Can Type 1 diabetes progression be halted? Possible role of high dose vitamin D and omega 3 fatty acids. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(7), 1604-1609.
[PMID: 28429367]
[17]
Cadario, F.; Pozzi, E.; Rizzollo, S.; Stracuzzi, M.; Beux, S.; Giorgis, A.; Carrera, D.; Fullin, F.; Riso, S.; Rizzo, A.M.; Montorfano, G.; Bagnati, M.; Dianzani, U.; Caimmi, P.; Bona, G.; Ricordi, C. Vitamin D and ω-3 supplementations in mediterranean diet during the 1st year of overt type 1 diabetes: A cohort study. Nutrients, 2019, 11(9), 1-12.
[http://dx.doi.org/10.3390/nu11092158] [PMID: 31505819]
[18]
Li, X.; Bi, X.; Wang, S.; Zhang, Z.; Li, F.; Zhao, A.Z. Therapeutic potential of ω-3 polyunsaturated fatty acids in human autoimmune diseases. Front. Immunol., 2019, 10, 2241.
[http://dx.doi.org/10.3389/fimmu.2019.02241] [PMID: 31611873]
[19]
Stene, L.C.; Joner, G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am. J. Clin. Nutr., 2003, 78(6), 1128-1134.
[http://dx.doi.org/10.1093/ajcn/78.6.1128] [PMID: 14668274]
[20]
Cadario, F.; Savastio, S.; Ricotti, R.; Rizzo, A.M.; Carrera, D.; Maiuri, L.; Ricordi, C. Administration of vitamin D and high dose of omega 3 to sustain remission of type 1 diabetes. Eur. Rev. Med. Pharmacol. Sci., 2018, 22(2), 512-515.
[PMID: 29424911]
[21]
Rewers, M.; Davis, B.; Ludvigsson, J. Environmental risk factors for type 1 diabetes Marian HHS Public Access., 2016. 387, 2340-2348.
[22]
Infante, M.; Ricordi, C.; Sanchez, J.; Clare-Salzler, M.J.; Padilla, N.; Fuenmayor, V.; Chavez, C.; Alvarez, A.; Baidal, D.; Alejandro, R.; Caprio, M.; Fabbri, A. Influence of vitamin d on islet autoimmunity and beta-cell function in type 1 diabetes. Nutrients, 2019, 11(9), 2185.
[http://dx.doi.org/10.3390/nu11092185] [PMID: 31514368]
[23]
Ilonen, J.; Lempainen, J.; Veijola, R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol., 2019, 15, 635-650.
[http://dx.doi.org/10.1038/s41574-019-0254-y]
[24]
Dayan, C.M.; Korah, M.; Tatovic, D.; Bundy, B.N.; Herold, K.C. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet, 2019, 394, 1286-1296.
[http://dx.doi.org/10.1016/S0140-6736(19)32127-0]
[25]
Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 2010, 464(7293), 1293-1300.
[http://dx.doi.org/10.1038/nature08933] [PMID: 20432533]
[26]
Atkinson, M.A.; Eisenbarth, G.S.; Michels, A.W. Type 1 diabetes. Lancet, 2014, 383(9911), 69-82.
[http://dx.doi.org/10.1016/S0140-6736(13)60591-7] [PMID: 23890997]
[27]
Willcox, A.; Richardson, S.J.; Bone, A.J.; Foulis, A.K.; Morgan, N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol., 2009, 155(2), 173-181.
[http://dx.doi.org/10.1111/j.1365-2249.2008.03860.x] [PMID: 19128359]
[28]
Wolden-Kirk, H.; Rondas, D.; Bugliani, M.; Korf, H.; Van Lommel, L.; Brusgaard, K.; Christesen, H.T.; Schuit, F.; Proost, P.; Masini, M.; Marchetti, P.; Eizirik, D.L.; Overbergh, L.; Mathieu, C. Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans. Endocrinology, 2014, 155(3), 736-747.
[http://dx.doi.org/10.1210/en.2013-1409] [PMID: 24424042]
[29]
DiMeglio, L.A.; Evans-Molina, C.; Oram, R.A. Type 1 diabetes. Lancet, 2018, 391(10138), 2449-2462.
[http://dx.doi.org/10.1016/S0140-6736(18)31320-5] [PMID: 29916386]
[30]
Lachin, J.M.; McGee, P.; Palmer, J.P. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes, 2014, 63(2), 739-748.
[http://dx.doi.org/10.2337/db13-0881] [PMID: 24089509]
[31]
King, A.J.F. The use of animal models in diabetes research. Br. J. Pharmacol., 2012, 166(3), 877-894.
[http://dx.doi.org/10.1111/j.1476-5381.2012.01911.x] [PMID: 22352879]
[32]
Al-Awar, A.; Kupai, K.; Veszelka, M.; Szucs, G.; Attieh, Z.; Murlasits, Z. Experimental diabetes mellitus in different animal models. J. Diabetes Res., 2016, 2016, 9051426.
[33]
Acharjee, S.; Ghosh, B.; Al-Dhubiab, B.E.; Nair, A.B. Understanding type 1 diabetes: Etiology and models. Can. J. Diabetes, 2013, 37, 269-276.
[http://dx.doi.org/10.1016/j.jcjd.2013.05.001]
[34]
Hawa, M.I.; Valorani, M.G.; Buckley, L.R.; Beales, P.E.; Afeltra, A.; Cacciapaglia, F.; Leslie, R.D.; Pozzilli, P. Lack of effect of vitamin D administration during pregnancy and early life on diabetes incidence in the non-obese diabetic mouse. Horm. Metab. Res., 2004, 36(9), 620-624.
[http://dx.doi.org/10.1055/s-2004-825926] [PMID: 15486813]
[35]
Makino, S.; Kunimoto, K.; Muraoka, Y.; Mizushima, Y.; Katagiri, K.; Tochino, Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu, 1980, 29(1), 1-13.
[http://dx.doi.org/10.1538/expanim1978.29.1_1] [PMID: 6995140]
[36]
Pearson, J.A.; Wong, F.S.; Wen, L. The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun., 2016, 66, 76-88.
[37]
Anderson, M.S.; Bluestone, J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol., 2005, 23, 447-485.
[http://dx.doi.org/10.1146/annurev.immunol.23.021704.115643] [PMID: 15771578]
[38]
Harada, M.; Makino, S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia, 1984, 27(6), 604-606.
[http://dx.doi.org/10.1007/BF00276978] [PMID: 6530055]
[39]
Caquard, M.; Ferret-Bernard, S.; Haurogné, K.; Ouary, M.; Allard, M.; Jégou, D.; Bach, J.M.; Lieubeau, B. Diabetes acceleration by cyclophosphamide in the non-obese diabetic mouse is associated with differentiation of immunosuppressive monocytes into immunostimulatory cells. Immunol. Lett., 2010, 129(2), 85-93.
[http://dx.doi.org/10.1016/j.imlet.2010.01.009] [PMID: 20144655]
[40]
Brode, S.; Raine, T.; Zaccone, P.; Cooke, A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol., 2006, 177(10), 6603-6612.
[http://dx.doi.org/10.4049/jimmunol.177.10.6603] [PMID: 17082572]
[41]
Radenković, M.; Stojanović, M.; Prostran, M. Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. J. Pharmacol. Toxicol. Methods, 2016, 78, 13-31.
[http://dx.doi.org/10.1016/j.vascn.2015.11.004] [PMID: 26596652]
[42]
Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia, 2008, 51(2), 216-226.
[http://dx.doi.org/10.1007/s00125-007-0886-7] [PMID: 18087688]
[43]
Ighodaro, O.M.; Adeosun, A.M.; Akinloye, O.A. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas), 2017, 53(6), 365-374.
[http://dx.doi.org/10.1016/j.medici.2018.02.001] [PMID: 29548636]
[44]
Szkudelski, T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res., 2001, 50(6), 537-546.
[PMID: 11829314]
[45]
Goyal, S.N.; Reddy, N.M.; Patil, K.R.; Nakhate, K.T.; Ojha, S.; Patil, C.R. Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem. Biol. Interact., 2016, 244, 49-63.
[http://dx.doi.org/10.1016/j.cbi.2015.11.032]
[46]
Charoenngam, N.; Holick, M.F. Immunologic effects of vitamin D on human health and disease. Nutrients, 2020, 12(7), 2097.
[http://dx.doi.org/10.3390/nu12072097] [PMID: 32679784]
[47]
Bellan, M.; Andreoli, L.; Mele, C.; Sainaghi, P.P.; Rigamonti, C.; Piantoni, S.; De Benedittis, C.; Aimaretti, G.; Pirisi, M.; Marzullo, P. Pathophysiological role and therapeutic implications of vitamin D in autoimmunity: Focus on chronic autoimmune diseases. Nutrients, 2020, 12(3), 789.
[http://dx.doi.org/10.3390/nu12030789] [PMID: 32192175]
[48]
Hyppönen, E. Vitamin D and increasing incidence of type 1 diabetes-evidence for an association? Diabetes Obes. Metab., 2010, 12(9), 737-743.
[http://dx.doi.org/10.1111/j.1463-1326.2010.01211.x] [PMID: 20649624]
[49]
Takiishi, T.; Gysemans, C.; Bouillon, R.; Mathieu, C. Vitamin D and diabetes. Rheum. Dis. Clin. North Am., 2012, 38, 179-206.
[http://dx.doi.org/10.1016/j.rdc.2012.03.015]
[50]
Akdere, G.; Efe, B.; Sisman, P.; Yorulmaz, G. The relationship between vitamin D level and organ-specifi c autoimmune disorders in newly diagnosed type I diabetes mellitus. Bratisl Med, 2018, 119, 544-549.
[51]
Pike, J.W.; Meyer, M.B. Fundamentals of vitamin D hormoneregulated gene expression. J. Steroid Biochem. Mol. Biol. 2014, 144(Pt A), 5-11.
[http://dx.doi.org/10.1016/j.jsbmb.2013.11.004] [PMID: 24239506]
[52]
Hyppönen, E.; Läärä, E.; Reunanen, A.; Järvelin, M.R.; Virtanen, S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet, 2001, 358(9292), 1500-1503.
[http://dx.doi.org/10.1016/S0140-6736(01)06580-1] [PMID: 11705562]
[53]
Mathieu, C.; Waer, M.; Casteels, K.; Laureys, J.; Bouillon, R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology, 1995, 136(3), 866-872.
[http://dx.doi.org/10.1210/endo.136.3.7867594] [PMID: 7867594]
[54]
Casteels, K.; Waer, M.; Bouillon, R.; Depovere, J.; Valckx, D.; Laureys, J.; Mathieu, C. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin. Exp. Immunol., 1998, 112(2), 181-187.
[http://dx.doi.org/10.1046/j.1365-2249.1998.00568.x] [PMID: 9649179]
[55]
Gregori, S.; Giarratana, N.; Smiroldo, S.; Uskokovic, M.; Adorini, L.A. 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes, 2002, 51(5), 1367-1374.
[http://dx.doi.org/10.2337/diabetes.51.5.1367] [PMID: 11978632]
[56]
Driver, J.P.; Foreman, O.; Mathieu, C.; van Etten, E.; Serreze, D.V. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin. Exp. Immunol., 2008, 151(1), 76-85.
[http://dx.doi.org/10.1111/j.1365-2249.2007.03537.x] [PMID: 17983444]
[57]
Mathieu, C.; Van Etten, E.; Gysemans, C.; Decallonne, B.; Kato, S.; Laureys, J.; Depovere, J.; Valckx, D.; Verstuyf, A.; Bouillon, R. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J. Bone Miner. Res., 2001, 16(11), 2057-2065.
[http://dx.doi.org/10.1359/jbmr.2001.16.11.2057] [PMID: 11697802]
[58]
Zhang, X.; Zhou, M.; Guo, Y.; Song, Z.; Liu, B. 1,25-dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPARγ signaling pathway. BioMed Res. Int., 2015, 2015, 157834.
[59]
Mathieu, C.; Laureys, J.; Sobis, H.; Vandeputte, M.; Waer, M.; Bouillon, R. 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes, 1992, 41(11), 1491-1495.
[http://dx.doi.org/10.2337/diab.41.11.1491] [PMID: 1397723]
[60]
Mathieu, C.; Waer, M.; Laureys, J.; Rutgeerts, O.; Bouillon, R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia, 1994, 37(6), 552-558.
[http://dx.doi.org/10.1007/BF00403372] [PMID: 7926338]
[61]
Gysemans, C.A.; Cardozo, A.K.; Callewaert, H.; Giulietti, A.; Hulshagen, L.; Bouillon, R.; Eizirik, D.L.; Mathieu, C. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology, 2005, 146(4), 1956-1964.
[http://dx.doi.org/10.1210/en.2004-1322] [PMID: 15637289]
[62]
Casteels, K.; Waer, M.; Laureys, J.; Valckx, D.; Depovere, J.; Bouillon, R.; Mathieu, C. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation, 1998, 65(9), 1225-1232.
[http://dx.doi.org/10.1097/00007890-199805150-00014] [PMID: 9603172]
[63]
Bogdanou, D.; Penna-Martinez, M.; Filmann, N.; Chung, T.L.; Moran-Auth, Y.; Wehrle, J.; Cappel, C.; Huenecke, S.; Herrmann, E.; Koehl, U.; Badenhoop, K. T-lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover. Diabetes Metab. Res. Rev., 2017, 33(3), 1-11.
[http://dx.doi.org/10.1002/dmrr.2865] [PMID: 27764529]
[64]
Gysemans, C.; Van Etten, E.; Overbergh, L.; Verstuyf, A.; Waer, M.; Bouillon, R.; Mathieu, C. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-β in combination with an analogue of 1α,25-dihydroxyvitamin-D3. Clin. Exp. Immunol., 2002, 128(2), 213-220.
[http://dx.doi.org/10.1046/j.1365-2249.2002.01825.x] [PMID: 11985511]
[65]
Decallonne, B.; van Etten, E.; Overbergh, L.; Valckx, D.; Bouillon, R.; Mathieu, C. 1α,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J. Autoimmun., 2005, 24(4), 281-289.
[http://dx.doi.org/10.1016/j.jaut.2005.03.007] [PMID: 15913954]
[66]
Hull, C.M.; Peakman, M.; Tree, T.I.M. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? Diabetologia, 2017, 60(10), 1839-1850.
[http://dx.doi.org/10.1007/s00125-017-4377-1] [PMID: 28770318]
[67]
Salomon, B.; Lenschow, D.J.; Rhee, L.; Ashourian, N.; Singh, B.; Sharpe, A.; Bluestone, J.A. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 2000, 12(4), 431-440.
[http://dx.doi.org/10.1016/S1074-7613(00)80195-8] [PMID: 10795741]
[68]
Bock, G.; Prietl, B.; Mader, J.K.; Höller, E.; Wolf, M.; Pilz, S.; Graninger, W.B.; Obermayer-Pietsch, B.M.; Pieber, T.R. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab. Res. Rev., 2011, 27(8), 942-945.
[http://dx.doi.org/10.1002/dmrr.1276] [PMID: 22069289]
[69]
Gabbay, M.A.; Sato, M.N.; Finazzo, C.; Duarte, A.J.; Dib, S.A. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual b-cell function in new-onset type 1 diabetes mellitus. Diabetes Technol. Ther., 2012, 15, 601-607.
[70]
Takiishi, T.; Ding, L.; Baeke, F.; Spagnuolo, I.; Sebastiani, G.; Laureys, J.; Verstuyf, A.; Carmeliet, G.; Dotta, F.; Van Belle, T.L.; Gysemans, C.A.; Mathieu, C. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes, 2014, 63(6), 2026-2036.
[http://dx.doi.org/10.2337/db13-1559] [PMID: 24550187]
[71]
Treiber, G.; Prietl, B.; Fröhlich-Reiterer, E.; Lechner, E.; Ribitsch, A.; Fritsch, M. Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial. Clin. Immunol., 2015, 161, 217-224.
[http://dx.doi.org/10.1016/j.clim.2015.08.002]
[72]
Rose, K.; Penna-Martinez, M.; Klahold, E.; Kärger, D.; Shoghi, F.; Kahles, H.; Bayer, M.; Hintermann, E.; Pfeilschifter, J.M.; Badenhoop, K.; Ramos-Lopez, E.; Christen, U. Influence of the vitamin D plasma level and vitamin D-related genetic polymorphisms on the immune status of patients with type 1 diabetes: a pilot study. Clin. Exp. Immunol., 2013, 171(2), 171-185.
[http://dx.doi.org/10.1111/cei.12013] [PMID: 23286944]
[73]
Cnop, M.; Welsh, N.; Jonas, J-C.; Jörns, A.; Lenzen, S.; Eizirik, D.L. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005, 54(Suppl. 2), S97-S107.
[http://dx.doi.org/10.2337/diabetes.54.suppl_2.S97] [PMID: 16306347]
[74]
Ramos-Rodríguez, M.; Raurell-Vila, H.; Colli, M.L.; Alvelos, M.I.; Subirana-Granés, M.; Juan-Mateu, J.; Norris, R.; Turatsinze, J.V.; Nakayasu, E.S.; Webb-Robertson, B.M.; Inshaw, J.R.J.; Marchetti, P.; Piemonti, L.; Esteller, M.; Todd, J.A.; Metz, T.O.; Eizirik, D.L.; Pasquali, L. The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes. Nat. Genet., 2019, 51(11), 1588-1595.
[http://dx.doi.org/10.1038/s41588-019-0524-6] [PMID: 31676868]
[75]
Dean, J.W.; Peters, L.D.; Fuhrman, C.A.; Seay, H.R.; Posgai, A.L. Stimpson, SE Innate inflammation drives NK cell activation to impair Treg activity. J. Autoimmun., 2020, 108, 102417.
[http://dx.doi.org/10.1016/j.jaut.2020.102417]
[76]
Federico, G.; Focosi, D.; Marchi, B.; Randazzo, E.; De Donno, M. Vierucci, F Administering 25-hydroxyvitamin D3 in vitamin D-deficient young type 1A diabetic patients reduces reactivity against islet autoantigens. Clin. Nutr., 2014, 33, 1153-1156.
[http://dx.doi.org/10.1016/j.clnu.2014.01.001]
[77]
Shih, E.M.; Mittelman, S.; Pitukcheewanont, P.; Azen, C.G.; Monzavi, R. Effects of vitamin D repletion on glycemic control and inflammatory cytokines in adolescents with type 1 diabetes. Pediatr. Diabetes, 2016, 17(1), 36-43.
[http://dx.doi.org/10.1111/pedi.12238] [PMID: 25524404]
[78]
Dankers, W.; Colin, E.M.; van Hamburg, J.P.; Lubberts, E. Vitamin D in autoimmunity: Molecular mechanisms and therapeutic potential. Front. Immunol., 2017, 7, 697.
[http://dx.doi.org/10.3389/fimmu.2016.00697] [PMID: 28163705]
[79]
Lu, J.; Liu, J.; Li, L.; Lan, Y.; Liang, Y. Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets. Clin. Transl. Immunology, 2020, 9(3), e1122.
[http://dx.doi.org/10.1002/cti2.1122] [PMID: 32185024]
[80]
Aljabri, K.S.; Bokhari, S.A.; Khan, M.J. Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency. Ann. Saudi Med., 2010, 30(6), 454-458.
[http://dx.doi.org/10.4103/0256-4947.72265] [PMID: 21060157]
[81]
Savastio, S.; Cadario, F.; Genoni, G.; Bellomo, G.; Bagnati, M.; Secco, G.; Picchi, R.; Giglione, E.; Bona, G. Vitamin D deficiency and glycemic status in children and adolescents with type 1 diabetes mellitus. PLoS One, 2016, 11(9), e0162554.
[http://dx.doi.org/10.1371/journal.pone.0162554] [PMID: 27607348]
[82]
Dehkordi, E.H.; Dehkordi, V.H.; Fatemi, S.M.R.; Zolfaghari, M. Effect of vitamin d supplement therapy on hba1c and igf-1 levels in children with type 1 diabetes mellitus and vitamin D deficiency. Electron J. Gen. Med., 2018, 15, 4-9.
[http://dx.doi.org/10.29333/ejgm/93167]
[83]
Felício, K.M.; de Souza, A.C.C.B.; Neto, J.F.A.; de Melo, F.T.C.; Carvalho, C.T.; Arbage, T.P.; de Rider Brito, H.A.; Peixoto, A.S.; de Oliveira, A.F.; de Souza Resende, F.; Reis, S.S.; Motta, A.R.; da Costa Miranda, H.; Janau, L.C.; Yamada, E.S.; Felicio, J.S. Glycemic variability and insulin needs in patients with type 1 diabetes mellitus supplemented with vitamin D: A pilot study using continuous glucose monitoring system. Curr. Diabetes Rev., 2018, 14(4), 395-403.
[http://dx.doi.org/10.2174/1573399813666170616075013] [PMID: 28618984]
[84]
Panjiyar, R.P.; Dayal, D.; Attri, S.V.; Sachdeva, N.; Sharma, R.; Bhalla, A.K. Sustained serum 25-hydroxyvitamin D concentrations for one year with cholecalciferol supplementation improves glycaemic control and slows the decline of residual β cell function in children with type 1 diabetes. Pediatr. Endocrinol. Diabetes Metab., 2018, 2018(3), 111-117.
[http://dx.doi.org/10.5114/pedm.2018.80992] [PMID: 30786675]
[85]
Ahmed, A.E-A.; Sakhr, H.M.; Hassan, M.H.; El-Amir, M.I.; Ameen, H.H. Vitamin D receptor rs7975232, rs731236 and rs1544410 single nucleotide polymorphisms, and 25-hydroxyvitamin D levels in Egyptian children with type 1 diabetes mellitus: effect of vitamin D co-therapy. Diabetes Metab. Syndr. Obes., 2019, 12, 703-716.
[http://dx.doi.org/10.2147/DMSO.S201525] [PMID: 31190930]
[86]
Pitocco, D.; Crinò, A.; Di Stasio, E.; Manfrini, S.; Guglielmi, C.; Spera, S.; Anguissola, G.B.; Visalli, N.; Suraci, C.; Matteoli, M.C.; Patera, I.P.; Cavallo, M.G.; Bizzarri, C.; Pozzilli, P. The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet. Med., 2006, 23(8), 920-923.
[http://dx.doi.org/10.1111/j.1464-5491.2006.01921.x] [PMID: 16911633]
[87]
Ataie-Jafari, A.; Loke, S.C.; Rahmat, A.B.; Larijani, B.; Abbasi, F.; Leow, M.K.S. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin. Nutr., 2013, 32, 911-7.
[http://dx.doi.org/10.1016/j.clnu.2013.01.012]
[88]
Araujo, D.B.; Dantas, J.R.; Silva, K.R.; Souto, D.L.; Pereira, M.F.C.; Moreira, J.P.; Luiz, R.R.; Claudio-Da-Silva, C.S.; Gabbay, M.A.L.; Dib, S.A.; Couri, C.E.B.; Maiolino, A.; Rebelatto, C.L.K.; Daga, D.R.; Senegaglia, A.C.; Brofman, P.R.S.; Baptista, L.S.; Oliveira, J.E.P.; Zajdenverg, L.; Rodacki, M. Allogenic adipose tissue-derived stromal/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: A 3-month follow-up pilot study. Front. Immunol., 2020, 11, 993.
[http://dx.doi.org/10.3389/fimmu.2020.00993] [PMID: 32582156]
[89]
Walter, M.; Kaupper, T.; Adler, K.; Foersch, J.; Bonifacio, E.; Ziegler, A.G. No effect of the 1α,25-dihydroxyvitamin D3 on β-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care, 2010, 33(7), 1443-1448.
[http://dx.doi.org/10.2337/dc09-2297] [PMID: 20357369]
[90]
Hafez, M.; Hassan, M.; Musa, N.; Abdel Atty, S.; Azim, S.A. Vitamin D status in Egyptian children with type 1 diabetes and the role of vitamin D replacement in glycemic control. J. Pediatr. Endocrinol. Metab., 2017, 30(4), 389-394.
[http://dx.doi.org/10.1515/jpem-2016-0292] [PMID: 27997353]
[91]
Ordooei, M.; Shojaoddiny-Ardekani, A.; Hoseinipoor, S.H.; Miroliai, M.; Zare-Zardini, H. Effect of vitamin D on HbA1c levels of children and adolescents with diabetes mellitus type 1. Minerva Pediatr., 2017, 69(5), 391-395.
[PMID: 25411949]
[92]
Sharma, S.; Biswal, N.; Bethou, A.; Rajappa, M.; Kumar, S.; Vinayagam, V. Does vitamin D supplementation improve glycaemic control in children with type 1 diabetes mellitus? - A randomized controlled trial. J. Clin. Diagn. Res., 2017, 11(9), SC15-SC17.
[http://dx.doi.org/10.7860/JCDR/2017/27321.10645] [PMID: 29207798]
[93]
Bizzarri, C.; Pitocco, D.; Napoli, N.; Di Stasio, E.; Maggi, D.; Manfrini, S.; Suraci, C.; Cavallo, M.G.; Cappa, M.; Ghirlanda, G.; Pozzilli, P. No protective effect of calcitriol on β-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care, 2010, 33(9), 1962-1963.
[http://dx.doi.org/10.2337/dc10-0814] [PMID: 20805274]
[94]
International Diabetes Federation. Ogle, G.; Misddlehurst, A.; Silink, M. Hanas, R., Eds.; In: Pocketbook for managing diabetes in childhood and adolescence in under-resourced countries, 2nd ed; Brussels, 2017.
[95]
Yazdanpanah, S.; Rabiee, M.; Tahriri, M.; Abdolrahim, M.; Rajab, A.; Jazayeri, H.E.; Tayebi, L. Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: A comprehensive review. Crit. Rev. Clin. Lab. Sci., 2017, 54(4), 219-232.
[http://dx.doi.org/10.1080/10408363.2017.1299684] [PMID: 28393586]
[96]
Perchard, R.; Magee, L.; Whatmore, A.; Ivison, F.; Murray, P.; Stevens, A.; Mughal, M.Z.; Ehtisham, S.; Campbell, J.; Ainsworth, S.; Marshall, M.; Bone, M.; Doughty, I.; Clayton, P.E. A pilot interventional study to evaluate the impact of cholecalciferol treatment on HbA1c in type 1 diabetes (T1D). Endocr. Connect., 2017, 6(4), 225-231.
[http://dx.doi.org/10.1530/EC-17-0045] [PMID: 28381562]
[97]
Hafez, M.; Musa, N.; Abdel Atty, S.; Ibrahem, M.; Abdel Wahab, N. Effect of vitamin D supplementation on lipid profile in vitamin D-deficient children with type 1 diabetes and dyslipidemia. Horm. Res. Paediatr., 2019, 91(5), 311-318.
[http://dx.doi.org/10.1159/000500829] [PMID: 31266036]
[98]
Cholewski, M.; Tomczykowa, M.; Tomczyk, M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. Nutrients, 2018, 10(11), 1662.
[http://dx.doi.org/10.3390/nu10111662] [PMID: 30400360]
[99]
Román, G.C.; Jackson, R.E.; Gadhia, R.; Román, A.N.; Reis, J. Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease. Rev. Neurol. (Paris), 2019, 175(10), 724-741.
[http://dx.doi.org/10.1016/j.neurol.2019.08.005] [PMID: 31521398]
[100]
Kouchaki, E.; Afarini, M.; Abolhassani, J.; Mirhosseini, N.; Bahmani, F.; Masoud, S.A.; Asemi, Z. High-dose ω-3 fatty acid plus Vitamin D 3 supplementation affects clinical symptoms and metabolic status of patients with multiple sclerosis: A randomized controlled clinical trial. J. Nutr., 2018, 148(8), 1380-1386.
[http://dx.doi.org/10.1093/jn/nxy116] [PMID: 29982544]
[101]
Serhan, C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature, 2014, 510(7503), 92-101.
[http://dx.doi.org/10.1038/nature13479] [PMID: 24899309]
[102]
Nelson, J.R.; Raskin, S. The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgrad. Med., 2019, 131(4), 268-277.
[http://dx.doi.org/10.1080/00325481.2019.1607414] [PMID: 31063407]
[103]
Serhan, C.N. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol., 2010, 177(4), 1576-1591.
[http://dx.doi.org/10.2353/ajpath.2010.100322] [PMID: 20813960]
[104]
Calder, P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids, 2003, 38(4), 343-352.
[http://dx.doi.org/10.1007/s11745-003-1068-y] [PMID: 12848278]
[105]
Norris, J.M.; Yin, X.; Lamb, M.M.; Barriga, K.; Seifert, J.; Hoffman, M.; Orton, H.D.; Barón, A.E.; Clare-Salzler, M.; Chase, H.P.; Szabo, N.J.; Erlich, H.; Eisenbarth, G.S.; Rewers, M. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA, 2007, 298(12), 1420-1428.
[http://dx.doi.org/10.1001/jama.298.12.1420] [PMID: 17895458]
[106]
Niinistö, S.; Takkinen, H.M.; Erlund, I.; Ahonen, S.; Toppari, J.; Ilonen, J.; Veijola, R.; Knip, M.; Vaarala, O.; Virtanen, S.M. Fatty acid status in infancy is associated with the risk of type 1 diabetes-associated autoimmunity. Diabetologia, 2017, 60(7), 1223-1233.
[http://dx.doi.org/10.1007/s00125-017-4280-9] [PMID: 28474159]
[107]
Krishna Mohan, I.; Das, U.N. Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids. Nutrition, 2001, 17(2), 126-151.
[http://dx.doi.org/10.1016/S0899-9007(00)00468-8] [PMID: 11240341]
[108]
Löfvenborg, J.E.; Andersson, T.; Carlsson, P-O.; Dorkhan, M.; Groop, L.; Martinell, M.; Tuomi, T.; Wolk, A.; Carlsson, S. Fatty fish consumption and risk of latent autoimmune diabetes in adults. Nutr. Diabetes, 2014, 4, e139-e139.
[http://dx.doi.org/10.1038/nutd.2014.36] [PMID: 25329601]
[109]
Bellenger, J.; Bellenger, S.; Bataille, A.; Massey, K.A.; Nicolaou, A.; Rialland, M.; Tessier, C.; Kang, J.X.; Narce, M. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes, 2011, 60(4), 1090-1099.
[http://dx.doi.org/10.2337/db10-0901] [PMID: 21330635]
[110]
Davanso, M.R.; Crisma, A.R.; Murata, G.; Newsholme, P.; Curi, R. Impact of dietary fatty acids on macrophage lipid metabolism, signaling and function. Immunometabolism, 2020, 2, 1-41.
[111]
Chase, H.P.; Boulware, D.; Rodriguez, H.; Donaldson, D.; Chritton, S.; Rafkin-Mervis, L.; Krischer, J.; Skyler, J.S.; Clare-Salzler, M. Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr. Diabetes, 2015, 16(4), 271-279.
[http://dx.doi.org/10.1111/pedi.12170] [PMID: 25039804]
[112]
Mølvig, J.; Pociot, F.; Worsaae, H.; Wogensen, L.D.; Baek, L.; Christensen, P.; Mandrup-Poulsen, T.; Andersen, K.; Madsen, P.; Dyerberg, J. Dietary supplementation with omega-3-polyunsaturated fatty acids decreases mononuclear cell proliferation and interleukin-1 β content but not monokine secretion in healthy and insulin-dependent diabetic individuals. Scand. J. Immunol., 1991, 34(4), 399-410.
[http://dx.doi.org/10.1111/j.1365-3083.1991.tb01563.x] [PMID: 1656517]
[113]
Sullivan, D.R.; Yue, D.K.; Capogreco, C.; McLennan, S.; Nicks, J.; Cooney, G.; Caterson, I.; Turtle, J.R.; Hensley, W.J. The effects of dietary n - 3 fatty acid in animal models of type 1 and type 2 diabetes. Diabetes Res. Clin. Pract., 1990, 9(3), 225-230.
[http://dx.doi.org/10.1016/0168-8227(90)90049-Y] [PMID: 2146101]
[114]
Landgraf-Leurs, M.M.C.; Drummer, C.; Fröschl, H.; Steinhuber, R.; Von Schacky, C.; Landgraf, R. Pilot study on ω-3 fatty acids in type I diabetes mellitus. Diabetes, 1990, 39(3), 369-375.
[http://dx.doi.org/10.2337/diab.39.3.369] [PMID: 2137803]
[115]
O’Mahoney, L.L.; Dunseath, G.; Churm, R.; Holmes, M.; Boesch, C.; Stavropoulos-Kalinoglou, A.; Ajjan, R.A.; Birch, K.M.; Orsi, N.M.; Mappa, G.; Price, O.J.; Campbell, M.D. Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovasc. Diabetol., 2020, 19(1), 127.
[http://dx.doi.org/10.1186/s12933-020-01094-5] [PMID: 32787879]
[116]
Stiefel, P.; Ruiz-Gutierrez, V.; Gajón, E.; Acosta, D.; García-Donas, M.A.; Madrazo, J.; Villar, J.; Carneado, J. Sodium transport kinetics, cell membrane lipid composition, neural conduction and metabolic control in type 1 diabetic patients. Changes after a low-dose n-3 fatty acid dietary intervention. Ann. Nutr. Metab., 1999, 43(2), 113-120.
[http://dx.doi.org/10.1159/000012775] [PMID: 10436310]
[117]
Gurol, A.O.; Okten-Kursun, A.; Kasapoglu, P.; Suzergoz, F.; Kucuksezer, U.C.; Cevik, A.; Tutuncu, Y.; Yentur, S.P.; Gurol, S.D.; Kucuk, M.; Yilmaz, M.T. The synergistic effect of ω3 and Vit D3 on glycemia and TNF-α in islet transplantation. Cell. Mol. Biol., 2016, 62(1), 90-98.
[PMID: 26828994]
[118]
An, W.S.; Lee, S.M.; Son, Y.K.; Kim, S.E.; Kim, K.H.; Han, J.Y. Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients. Nutr. Res., 2012, 32, 495-502.
[http://dx.doi.org/10.1016/j.nutres.2012.06.005]
[119]
Horvaticek, M.; Djelmis, J.; Ivanisevic, M.; Oreskovic, S.; Herman, M. Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: randomized placebo controlled clinical trial. Nature Publishing Group, 2017, 71(8), 968-972.
[http://dx.doi.org/10.1038/ejcn.2017.46] [PMID: 28378851]
[120]
Haller, M.J.; Wasserfall, C.H.; Hulme, M.A.; Cintron, M.; Brusko, T.M.; McGrail, K.M.; Wingard, J.R.; Theriaque, D.W.; Shuster, J.J.; Ferguson, R.J.; Kozuch, M.; Clare-Salzler, M.; Atkinson, M.A.; Schatz, D.A. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol. Blood Marrow Transplant., 2013, 19(7), 1126-1129.
[http://dx.doi.org/10.1016/j.bbmt.2013.04.011] [PMID: 23611977]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy